左旋咪唑诱导的血管病:系统综述
该系统综述检索MEDLINE 1972至2016年文献,纳入111篇文章、192例左旋咪唑诱导的血管病患者。患者以女性为主,皮肤受累最常见,ANCAs和/或APL抗体阳性率高,可伴白细胞减少及肾、肺受累,停药后多数预后良好但再暴露可复发。
要点
- 左旋咪唑诱导的血管病以女性为主,皮肤受累率94.8%,面部尤其是耳部多见。
- ANCAs阳性率93.8%,APL抗体阳性率67.9%,白细胞减少占50%。
- 多数患者停药后预后良好(86.6%),但再暴露可致复发(28.4%)。
核心结论
- 左旋咪唑诱导的血管病以女性为主,表现为皮肤受累、ANCA和/或APL抗体阳性、白细胞减少及血管炎或血栓性血管病组织学病变;尽管可有全身受累,停用左旋咪唑后预后良好。
研究设计与样本
- 系统综述,检索MEDLINE 1972至2016年发表的文献,检索到357篇参考文献和摘要,最终纳入111篇文章。
主要发现
- 192例患者中女性122例(63.5%),中位年龄44岁(四分位距38-50)。
- 皮肤受累182例(94.8%),皮损多见于面部136例(70.8%),尤其耳部;紫癜最常见131例(68.2%)。
- 急性肾衰竭24例(12.5%),肺部受累20例(10.4%)。
- ANCAs阳性167/178例(93.8%),抗MPO和抗PR3双特异性51/118例(43.2%);APL抗体阳性93/137例(67.9%);白细胞减少69/138例(50%)。
- 皮肤活检示血管炎73/148例(49.3%),血栓性血管病62/148例(41.9%);预后良好116/134例(86.6%),复发33例(28.4%),主要与再暴露有关。
关键数值与推荐
- ANCAs阳性率93.8%(167/178),APL抗体阳性率67.9%(93/137),白细胞减少50%(69/138)。
- 皮肤活检血管炎49.3%(73/148),血栓性血管病41.9%(62/148)。
- 预后良好86.6%(116/134),复发28.4%(33例),主要与再暴露有关。
临床怎么用
- 对疑似左旋咪唑诱导血管病患者应询问左旋咪唑暴露史,检测ANCA和APL抗体及血常规,必要时行皮肤活检,核心处理为停用左旋咪唑并避免再暴露。
局限性
- 本文为基于已发表文献的系统综述,未报告原始研究的偏倚评估、异质性分析及随访时长等信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize levamisole-induced vasculopathy. METHODS: We performed a systematic review searching MEDLINE for articles published from 1972 to 2016. RESULTS: We retrieved 357 references and abstracts and selected 111 articles. Levamisole-induced vasculopathy was reported in 192 patients, with a female predominance (n = 122, 63.5%). Median [interquartile range] age was 44 [38-50]. Skin was the most frequently involved organ (n = 182, 94.8%). Cutaneous lesions were mostly on the face (n = 136, 70.8%), especially the ears. Purpura (n = 131, 68.2%) was the most reported cutaneous lesion. Organ involvement included acute renal failure (n = 24, 12.5%), and pulmonary involvement (n = 20, 10.4%). Anti-neutrophil cytoplasmic antibodies (ANCAs) were found in 167/178 patients (93.8%), with both anti-myeloperoxydase and anti-proteinase 3 specificity reported in 51/118 patients (43.2%). Anti-phospholipid (APL) antibodies were found in 93/137 patients (67.9%). Leukopenia was detected in 69/138 patients (50%). Skin biopsies identified vasculitis and thrombotic vasculopathy in 73/148 (49.3%) and 62/148 (41.9%) patients, respectively. The outcome was favourable in 116/134 patients (86.6%), but relapses were reported in 33 (28.4%), mainly on levamisole re-exposure. CONCLUSION: Levamisole-induced vasculopathy is characterized by a female predominance, skin involvement, ANCA and/or APL antibody positivity, leukopenia, vasculitis or vascular thrombotic histological lesions, and despite possible systemic involvement, a favourable outcome with levamisole interruption.
引用
- Dartevel A, Chaigne B, Moachon L, et al. Levamisole-induced vasculopathy: A systematic review. Semin Arthritis Rheum. 2018. PMID: 30166200. doi:10.1016/j.semarthrit.2018.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。